The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.

开始日期2022-12-01

申办/合作机构

NYU Langone Health

[+1]

NCT02450279 / TerminatedN/A

Scintigraphic Comparison of Lung Deposition With Two Nebulizers During Invasive Mechanical Ventilation

Many devices are available for nebulising drug solution during invasive mechanical ventilation. Vibrating-mesh nebulizers ensure the highest lung deposition output. A recent international survey on aerosol therapy during mechanical ventilation (Ehrmann et al. 2013) reported that jet nebulizers remained the mostly used.
The aim of this study is to compare lung deposition of a radiolabeled administered with both nebulizers during invasive mechanical ventilation by planar scintigraphy.

开始日期2016-03-01

申办/合作机构

Cliniques Universitaires Saint-Luc

NCT02429817 / CompletedN/A

Tomographic Comparison of Aerosol Lung Distribution With Two Nebulizers Through a High Flow Nasal Cannula

Vibrating-mesh nebulizers ensure currently the best deposition output and are recommended in routine use in intensive care unit. However, jet nebulizers remain the most frequently used nebulizers.
On a bench study, aerosol delivery through a high flow nasal cannula (HFNC) was increased using a vibrating-mesh nebulizer as compared to a jet nebulizer.
Lung distribution of nebulized particles delivered through a HFNC has never been investigated in vivo. The aim of this study was to compare aerosol lung distribution with both nebulizers through a HFNC by SPECT-CT.

开始日期2015-04-01

申办/合作机构

Cliniques Universitaires Saint-Luc

100 项与锝[99mTc]喷替酸盐相关的临床结果

登录后查看更多信息

100 项与锝[99mTc]喷替酸盐相关的转化医学

登录后查看更多信息

100 项与锝[99mTc]喷替酸盐相关的专利（医药）

登录后查看更多信息

4,237

项与锝[99mTc]喷替酸盐相关的文献（医药）

2025-01-01·Journal of Environmental Sciences

Enhancing microbial superoxide generation and conversion to hydroxyl radicals for enhanced bioremediation using iron-binding ligands

Article

作者: Wang, Aijie ; Ning, Xue ; Wang, Yuhan ; Qu, Jiuhui ; Liang, Jinsong

Harnessing bacteria for superoxide production in bioremediation holds immense promise, yet its practical application is hindered by slow production rates and the relatively weak redox potential of superoxide. This study delves into a cost-effective approach to amplify superoxide production using an Arthrobacter strain, a prevalent soil bacterial genus. Our research reveals that introducing a carbon source along with specific iron-binding ligands, including deferoxamine (DFO), diethylenetriamine pentaacetate (DTPA), citrate, and oxalate, robustly augments microbial superoxide generation. Moreover, our findings suggest that these iron-binding ligands play a pivotal role in converting superoxide into hydroxyl radicals by modulating the electron transfer rate between Fe(III)/Fe(II) and superoxide. Remarkably, among the tested ligands, only DTPA emerges as a potent promoter of this conversion process when complexed with Fe(III). We identify an optimal Fe(III) to DTPA ratio of approximately 1:1 for enhancing hydroxyl radical production within the Arthrobacter culture. This research underscores the efficacy of simultaneously introducing carbon sources and DTPA in facilitating superoxide production and its subsequent conversion to hydroxyl radicals, significantly elevating bioremediation performance. Furthermore, our study reveals that DTPA augments superoxide production in cultures of diverse soils, with various soil microorganisms beyond Arthrobacter identified as contributors to superoxide generation. This emphasizes the universal applicability of DTPA across multiple bacterial genera. In conclusion, our study introduces a promising methodology for enhancing microbial superoxide production and its conversion into hydroxyl radicals. These findings hold substantial implications for the deployment of microbial reactive oxygen species in bioremediation, offering innovative solutions for addressing environmental contamination challenges.

2024-03-01·Carbohydrate polymers

Rapid self-healing carboxymethyl chitosan/hyaluronic acid hydrogels with injectable ability for drug delivery

Article

作者: Zhang, Fengjiao ; Feng, Yao ; Cui, Shuyuan ; Coseri, Sergiu ; Jing, Xiaokai ; Zhang, Sufeng

In this study, the quaternized carboxymethyl chitosan (QCMCS), oxidized hyaluronic acid (OHA), 3,3'-dithiobis-(propionohydrazide) (DTP) were used as raw materials for the synthesis of hydrogels with excellent properties as carriers for drug release. The hydrogels were prepared by a simple "one-pot" method without external stimuli on the basis of interactions between formed dynamic covalent bonds (imine bonds, acylhydrazone bonds, disulfide bonds) and hydrogen bonds. The hydrogels had rapid self-healing properties, with a self-healing rate of 96 % after 30 min, as well as good pH responsiveness and excellent cytocompatibility (up to 98 % cell survival). The compressive stress of the hydrogels reached 423 kPa. Moreover, a representative drug (acetylsalicylic acid) demonstrated sustained release in the hydrogels (>72 h). The drug release behaviour was shown to be consistent with the Fick diffusion mechanism by kinetic modelling. Collectively, the findings demonstrate that the QCMCS + OHA + DTP injectable self-healing hydrogels are a potential material for the construction of pH-controlled drug delivery platforms.

2024-03-01·Journal of neurosurgery

Radionuclide shuntography for cerebrospinal fluid shunt flow evaluation in adults

Article

作者: Klein, Jon P ; Alwakeal, Amr ; Avery, Ryan J ; Nandoliya, Khizar R ; Potts, Matthew B ; Linscheid, Logan

OBJECTIVE:

Radionuclide shuntography (RS) performed using 99mTc-DTPA injected into the reservoir of CSF shunts enables evaluation of CSF flow for suspected shunt malfunctions. The goal of this study was to report the authors’ institutional experience with RS and evaluate its utility and associated complications.

METHODS:

The authors retrospectively reviewed all RS studies performed between November 2003 and June 2022. Patients with shunted hydrocephalus who were ≥ 18 years of age were included. Patients undergoing RS for evaluation of Ommaya reservoirs were excluded. Demographics, hydrocephalus etiology, presenting symptoms, study results, subsequent management, complications, and intraoperative diagnoses were recorded. Chi-square tests were reported for categorical variables and standard 2 × 2 contingency methods were used for sensitivity/specificity analysis.

RESULTS:

The authors identified 211 RS procedures performed in 142 patients. The mean age at procedure was 55.6 ± 20.9 years (mean ± SD). Normal pressure hydrocephalus was the most common hydrocephalus etiology (37.0%), followed by congenital malformations (26.1%) and idiopathic intracranial hypertension (15.6%). Successful radionuclide injection was achieved in 207 studies (98.1%). Shunt patency was confirmed in 63.8% of successful injections, whereas malfunction was demonstrated in 27.1% and abnormally slow flow was seen in 9.2%. RS studies demonstrating shunt malfunction were more likely to result in subsequent revisions than were studies showing patency (86.6% vs 2.9%; p < 0.0001). The overall sensitivity and specificity of RS for detecting shunt malfunction was 92.3% and 96.2%, respectively. The median follow-up time was 29 months, with 151 cases having ≥ 6 months of follow-up. There were no complications or infections attributable to RS in this cohort.

CONCLUSIONS:

RS is a useful and safe tool in the workup of shunt malfunction.

项与锝[99mTc]喷替酸盐相关的新闻（医药）

2024-06-11

·PRNewswire

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight

The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of exposure to radiological or nuclear emergencies, and the increasing focus of nuclear-capable nations on safeguarding against radiation. These trends are expected to fuel the expansion of the anti-radiation drugs market from 2024 to 2030. LAS VEGAS, June 11, 2024 /PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation drugs companies' market shares, challenges, anti-radiation drugs market drivers, barriers, trends, and key market anti-radiation drugs companies in the market. Key Takeaways from the Anti-Radiation Drugs Market Report As per DelveInsight estimates, North America is anticipated to dominate the global anti-radiation drugs market during the forecast period. In the compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category had a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide. Notable anti-radiation drugs companies such as Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and several others, are currently operating in the anti-radiation drugs market. In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs. In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California. In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). To read more about the latest highlights related to the anti-radiation drugs market, get a snapshot of the key highlights entailed in the Global Anti-Radiation Drugs Market Report Anti-Radiation Drugs Overview Anti-radiation drugs are pharmaceutical compounds designed to mitigate the damaging effects of radiation exposure on the human body. These drugs work by either scavenging free radicals generated by radiation or by enhancing the repair mechanisms of cells damaged by radiation. One class of anti-radiation drugs includes radioprotectors, which are administered before radiation exposure to prevent or reduce its harmful effects. Another class, known as radiomitigators, is given after exposure to alleviate the severity of radiation-induced damage. These drugs hold significant promise in scenarios such as nuclear accidents, medical radiation therapy, and space travel, where the risk of radiation exposure is a concern. Research into anti-radiation drugs is ongoing, with scientists continually striving to improve their efficacy and minimize side effects. Some compounds under investigation show potential not only in protecting against acute radiation sickness but also in mitigating long-term effects such as cancer development. As our understanding of radiation biology advances, coupled with advancements in drug development technologies, the prospects for more effective and accessible anti-radiation drugs continue to brighten, offering hope for safer environments in radiation-prone situations. Anti-Radiation Drugs Market Insights In 2023, North America dominated the anti-radiation drugs market, primarily due to several factors contributing to growth. These include a substantial patient population afflicted with various illnesses like cancer, increasing numbers of diagnostic procedures, and governmental initiatives aimed at public health in the region. This trend is expected to continue from 2024 to 2030. The prevalence of cancer in the United States, for example, drives a significant demand for anti-radiation drugs. Statistics from the American Cancer Society projected around 2 million new cancer cases in the United States in 2024, leading to heightened demand for these drugs to support cancer diagnostic procedures. Additionally, the US benefits from a strong focus on clinical research and the presence of leading pharmaceutical companies, further bolstering the market for anti-radiation drugs. Moreover, in 2022, the US Department of Health and Human Services (HHS) allocated USD 290 million for the purchase of Nplate, a drug produced by Amgen USA Inc., intended to treat radiation sickness in the event of a nuclear emergency. This investment reflects ongoing efforts to enhance preparedness for radiological and nuclear emergencies and underscores the commitment to saving lives in such scenarios. To know more about why North America is leading the market growth in the anti-radiation drugs market, get a snapshot of the Anti-Radiation Drugs Market Outlook Anti-Radiation Drugs Market Dynamics The market dynamics of anti-radiation drugs are driven by a complex interplay of factors ranging from technological advancements to geopolitical events and regulatory frameworks. One of the primary drivers is the increasing threat of radiation exposure from various sources such as nuclear accidents, medical procedures, and potential radiological terrorism. This heightened awareness has propelled research and development efforts to create effective anti-radiation drugs that can mitigate the harmful effects of radiation exposure. Moreover, the growing prevalence of cancer and the widespread use of radiation therapy as a treatment modality has further fueled the demand for anti-radiation drugs. As more individuals undergo radiation-based treatments, there is a parallel need for medications that can protect healthy tissues and organs from the damaging effects of ionizing radiation. The competitive landscape of the anti-radiation drugs market is characterized by both established pharmaceutical companies and innovative startups vying for market share. Established players often leverage their resources and expertise to develop and commercialize new anti-radiation drugs, while startups focus on disruptive technologies and novel approaches to address unmet needs in radiation protection. Government initiatives and regulatory frameworks also play a crucial role in shaping the market dynamics of anti-radiation drugs. Regulatory agencies set standards for safety, efficacy, and quality assurance, which impact the development, approval, and commercialization of these medications. Additionally, government investments in research and development, as well as funding for procurement and stockpiling of anti-radiation drugs for emergency preparedness, influence market dynamics. Overall, the anti-radiation drugs market is characterized by a dynamic landscape driven by technological innovation, healthcare trends, regulatory factors, and geopolitical considerations. As the threat of radiation exposure continues to evolve, so too will the demand for effective anti-radiation drugs, driving further growth and innovation in this important sector of the pharmaceutical industry. Get a sneak peek at the anti-radiation drugs market dynamics @ Anti-Radiation Drugs Market Dynamics Analysis Anti-Radiation Drugs Market Assessment Anti-Radiation Drugs Market Segmentation Anti-Radiation Drugs Market Segmentation By Compound: Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and Others Anti-Radiation Drugs Market Segmentation By Indication: Acute Radiation Syndrome, Cancer Treatment, and Others Anti-Radiation Drugs Market Segmentation By Radiation Type: Ionizing Radiations and Non-Ionizing Radiations Anti-Radiation Drugs Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Anti-Radiation Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the anti-radiation drugs market are set to emerge as the trendsetter explore @ Anti-Radiation Drugs Companies Table of Contents Interested in knowing the anti-radiation drugs market by 2030? Click to get a snapshot of the Anti-Radiation Drugs Market Trends Related Reports Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, among others. Liquid Biopsy in Cancer Diagnostics Market Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key liquid biopsy in cancer diagnostics companies, including Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

放射疗法

2024-01-22

·Medical Design and Outsourcing

Potential bioelectric applications of organic mixed ionic–electronic conductors

Researchers in Korea say they found a way to potentially accelerate the development of high-performance organic electrochemical transistor devices with tunable transient responses. Organic mixed ionic-electronic conductors (OMIECs) offer potential bioelectric applications. Researchers at the Gwangju Institute of Science and Technology (GIST) used the transistors as platforms for testing the molecular orientation and ion injection directionality-dependent transient properties of OMIECs. Potential applications for OMIECs include computing and bio-fuel cells in addition to bioelectronics. The researchers say that, to ensure a wider acceptance of these materials, there remains a need to diversify their properties and develop techniques for application-specific OMIEC tailoring. They cite a “severe” lack of research on the molecular orientation-dependent transient behaviors of such conductors. The team at GIST, consisting of researchers from both Korea and the UK, set out to bridge the gap in understanding there. Professor Myung-Han Yoon from the GIST School of Materials Science and Engineering led the researchers. They explored the transient behaviors of OMIECs governed by variations in molecular orientation with the help of an organic electrochemical transistor (OECT). “OECTs are known to mimic the computing mechanisms of neurons and synapses in spiking neural networks (SNNs) and are thus considered promising,” said Yoon. “To aid the growing interest in exploring the dynamic behaviors of OECTs at the frequency domain, we focused on an aspect that is often overlooked. We decided to investigate the correlation between backbone planarity-dependent molecular orientation and transient OECT characteristics.” First, they synthesized two new 1,4-dithienylphenylene (DTP)-based OMEICs, DTP-2T and DTP-P, with co-monomer units, 2,2’-bithiophene and phenylene, respectively. According to GIST, the polymers comprised the same ionic and electronic properties. However, by manipulating the polymer backbone planarity, the researchers controlled the dominant molecular orientation of the mixed conductor system. This polymer then successfully helped to fabricate OECT devices. The team found that the polymers showed similar electrochemical properties despite having different molecular orientations. They then changed the ion injection direction when observing a certain current/voltage during the analysis. In the analysis, the researchers saw that ion injection relative to the molecular orientation affected the length of the ion drift pathway. This, in turn, resulted in peculiar transient responses in OECT devices. The team believes it could use its research to facilitate the design and development of advanced organic mixed conductor materials for biomolecular and biosignal sensors. “OECT-based SNN architectures are anticipated to replace current computing systems in the future by increasing computation speed and reducing energy consumption,” Yoon said. “Our findings are expected to facilitate the realization of SNN-based computing systems soon.”

2023-10-20

·蒲公英Ouryao

药典委：八个化药、九个中药药品标准公示

来源：国家药典委编辑：wangxinglai20042023年10月20日，国家药典委发布了药品标准修订公示，涉及八个化药品种（其中化学制剂药品5个、化学原料药3个）、九个中药品种（其中中药制剂2个、中药材及饮片7个），除参玉补气酒公示期为1个月外、其余品种公示期全部为3个月。一、化学药品： 01 米格列奈钙胶囊我委拟制定米格列奈钙胶囊国家药品标准。为确保标准的科学性、合理性和适用性，现将拟制定的米格列奈钙胶囊国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：程奇蕾电话：010-67079557通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 02 米格列奈钙片我委拟制定米格列奈钙片国家药品标准。为确保标准的科学性、合理性和适用性，现将拟制定的米格列奈钙片国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：程奇蕾电话：010-67079557通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 03 米格列奈钙我委拟制定米格列奈钙国家药品标准。为确保标准的科学性、合理性和适用性，现将拟制定的米格列奈钙国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：程奇蕾电话：010-67079557通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 04 锝[99mTc]喷替酸盐注射液我委拟修订锝[99mTc]喷替酸盐注射液国家药品标准，标准编号：《中国药典》2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的锝[99mTc]喷替酸盐注射液国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：程奇蕾电话：010-67079557通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 05 奥扎格雷钠我委拟修订奥扎格雷钠国家药品标准，标准编号：中国药典2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的奥扎格雷钠国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华电话：010-67079576通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 06 注射用奥扎格雷钠我委拟修订注射用奥扎格雷钠国家药品标准，标准编号：WS1-（X-076）-2002Z。为确保标准的科学性、合理性和适用性，现将拟修订的注射用奥扎格雷钠国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华电话：010-67079576通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 07 奥扎格雷钠注射液我委拟修订奥扎格雷钠注射液国家药品标准，标准编号：WS1-X-095-2005Z。为确保标准的科学性、合理性和适用性，现将拟修订的奥扎格雷钠注射液国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华电话：010-67079576通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 08 奥扎格雷我委拟修订奥扎格雷国家药品标准，标准编号：中国药典2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的奥扎格雷国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华电话：010-67079576通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061二、中药品种： 01 调胃丹我委拟修订调胃丹国家药品标准，标准编号：WS3-B-0395-90。为确保标准的科学性、合理性和适用性，现将拟修订的调胃丹国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：赵宇新倪龙电话：010-67079523 67079592通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 03 参玉补气酒我委拟修订参玉补气酒国家药品标准，标准编号：WS-5942（B-0942）-2014Z。为确保标准的科学性、合理性和适用性，现将拟修订的参玉补气酒国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起一个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：赵宇新倪龙电话：010-67079523 67079592通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 03 石菖蒲我委拟修订石菖蒲国家药品标准，标准编号：《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的石菖蒲国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 04 皂角刺我委拟修订皂角刺国家药品标准，标准编号：《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的皂角刺国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 05 艾叶我委拟修订艾叶国家药品标准，标准编号：《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的艾叶国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 06 鲜竹沥我委拟修订鲜竹沥国家药品标准，标准编号：《中华人民共和国卫生部药品标准》中药材第一册。为确保标准的科学性、合理性和适用性，现将拟修订的鲜竹沥国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 07 广金钱草我委拟修订广金钱草国家药品标准，《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的广金钱草国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 08 地骨皮我委拟修订地骨皮国家药品标准，《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的地骨皮国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 09 肉桂我委拟修订肉桂国家药品标准，标准编号：《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的肉桂国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061

申请上市

100 项与锝[99mTc]喷替酸盐相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	锝[99mTc]喷替酸盐	-	DB14007

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肺部疾病	美国	Jubilant Draximage, Inc.初创企业	2017-12-26
脑疾病	美国	Jubilant Draximage, Inc.初创企业	1989-12-29
肾脏疾病	美国	Jubilant Draximage, Inc.初创企业	1989-12-29
诊断试剂	日本	PDRadiopharma, Inc.	1979-05-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
癌症	临床1期	-	University of California San Diego	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ERS2021	N/A	弥漫性硬皮病 KL-6 \| SP-D	58	Tc99m – DTPA aerosols	膚餘願艱夢餘廠顧構獵(鏇窪繭築觸糧膚壓築積) = 網蓋艱襯繭鹽艱壓鹽襯餘鑰鹹夢膚築觸窪蓋壓 (遞鑰夢遞選願製壓築憲, 25.7)	积极	2021-09-05
AUA2017	N/A	-	699	DIETHYLENE TRIAMINE PENTA-ACETIC ACID (DTPA) (Group 1)	觸繭壓衊網鑰窪顧淵築(廠遞鏇選夢築鹽顧鹹鏇) = 觸醖觸鑰鑰膚範選鬱鑰獵觸觸夢顧窪觸鬱築顧 (醖艱夢蓋積鹽範廠壓顧 ) 更多	-	2017-04-01
				DIETHYLENE TRIAMINE PENTA-ACETIC ACID (DTPA) (Group 2)	觸繭壓衊網鑰窪顧淵築(廠遞鏇選夢築鹽顧鹹鏇) = 繭艱艱窪壓顧餘積網齋獵觸觸夢顧窪觸鬱築顧 (醖艱夢蓋積鹽範廠壓顧 ) 更多
Pubmed \| Eur Respir J	N/A	肺囊性纤维化	-	DTPA (CF subjects)	廠積顧夢齋膚簾觸壓壓(憲淵鬱鏇繭獵鹽選蓋觸) = 鹹糧膚夢選膚鏇鏇齋鏇鹽積餘艱窪艱積餘築遞 (鑰願繭淵淵廠鏇鬱築憲 )	-	2010-04-01
				DTPA (Control subjects)	廠積顧夢齋膚簾觸壓壓(憲淵鬱鏇繭獵鹽選蓋觸) = 糧淵築簾憲蓋壓齋鹹積鹽積餘艱窪艱積餘築遞 (鑰願繭淵淵廠鏇鬱築憲 )